Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 15;17(9):e0273914.
doi: 10.1371/journal.pone.0273914. eCollection 2022.

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)

Irini Sereti  1 , Kathryn Shaw-Saliba  2 , Lori E Dodd  2 , Robin L Dewar  3 , Sylvain Laverdure  4 , Shawn Brown  5 , Olivier Tshiani Mbaya  6 , Jean Jacques Muyembe Tamfum  7 , Placide Mblala-Kingebeni  7 , Ydrissa Sow  2 , Esther Akpa  2 , Mory Cherif Haidara  8 , Karine Fouth Tchos  2 , Abdoul Habib Beavogui  8 , Aaron Neal  2 , Dona Arlinda  9 , Dewi Lokida  10 , Louis Grue  6 , Mary Smolskis  2 , Laura A McNay  2 , Dehkontee Gayedyu-Dennis  11 , Guillermo M Ruiz-Palacios  12 , Abelardo Montenegro-Liendo  13 , Moctar Tounkara  14 , Seydou Samake  14 , Ganbolor Jargalsaikhan  15 , Delgersaikhan Zulkhuu  15 , Shera Weyers  6 , Tyler Bonnett  6 , Gail E Potter  2 , Randy Stevens  5 , Adam Rupert  5 , Jamila Aboulhab  2 , Jean-Luc Biampata  7 , Alexandre Delamo  8 , Bienvenu Salim Camara  8 , Herman Kosasih Indonesia  10 , Muhammad Karyana  9 , James T Duworko  11 , Justino Regalado-Pineda  16 , Paola Del Carmen Guerra-de-Blas  13 , Seydou Doumbia  14 , Djeneba Dabitao  14 , Naranjargal Dashdorj  15 , Naranbaatar Dashdorj  15 , Kevin Newell  6 , Alyson Francis  17 , Kevin Rubenstein  6 , Victoria Bera  17 , Iman Gulati  17 , Ratna Sardana  2 , Monica Millard  6 , Renee Ridzon  2 , Sally Hunsberger  2
Affiliations

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)

Irini Sereti et al. PLoS One. .

Erratum in

  • Correction: Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE).
    Sereti I, Shaw-Saliba K, Dodd LE, Dewar RL, Laverdure S, Brown S, Mbaya OT, Muyembe Tamfum JJ, Mblala-Kingebeni P, Sow Y, Akpa E, Haidara MC, Tchos KF, Beavogui AH, Neal A, Arlinda D, Lokida D, Grue L, Smolskis M, McNay LA, Gayedyu-Dennis D, Ruiz-Palacios GM, Montenegro-Liendo A, Tounkara M, Samake S, Jargalsaikhan G, Zulkhuu D, Weyers S, Bonnett T, Potter GE, Stevens R, Rupert A, Aboulhab J, Biampata JL, Delamou A, Camara BS, Indonesia HK, Karyana M, Duworko JT, Regalado-Pineda J, Guerra-de-Blas PDC, Doumbia S, Dabitao D, Dashdorj N, Dashdorj N, Newell K, Francis A, Rubenstein K, Bera V, Gulati I, Sardana R, Millard M, Ridzon R, Hunsberger S. Sereti I, et al. PLoS One. 2024 Nov 14;19(11):e0314048. doi: 10.1371/journal.pone.0314048. eCollection 2024. PLoS One. 2024. PMID: 39541305 Free PMC article.

Abstract

In response to the COVID-19 pandemic, COVID-19 vaccines have been developed, and the World Health Oraganization (WHO) has granted emergency use listing to multiple vaccines. Studies of vaccine immunogenicity data from implementing COVID-19 vaccines by national immunization programs in single studies spanning multiple countries and continents are limited but critically needed to answer public health questions on vaccines, such as comparing immune responses to different vaccines and among different populations.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Study schematic.
Fig 2
Fig 2. A. Current Enrollment Overall and by Country as of April 30, 2022.
Analysis population includes participants with complete data on receipt of initial or booster vaccine regimen, Visit 1 date, and manufacturer of first vaccine who met all eligibility criteria, provided informed consent within one day of receiving a COVID-19 vaccine, and were deemed eligible to continue to Visit 2. Data cleaning is ongoing as the study continues. B. Vaccines Received to Date in the Initial and Booster Cohorts as of April 30, 2022. Analysis population includes participants with complete data on receipt of initial or booster vaccine regimen, Visit 1 date, and manufacturer of first vaccine who also met all eligibility criteria, provided informed consent within one day of receiving a COVID-19 vaccine, and were deemed eligible to continue to Visit 2. Data cleaning is ongoing as the study continues.
See this image and copyright information in PMC

References

    1. WHO. WHO Coronavirus (COVID-19) Dashboard 2022 [Available from: https://covid19.who.int.
    1. WHO. Coronavirus disease (COVID-19): Vaccines 2021 [updated 19 February 2021. Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-....
    1. WHO. Landscape of observational studies on the effectiveness of COVID-19 vaccination 2022 [Available from: https://www.who.int/publications/m/item/draft-landscape-of-observational....
    1. Dashdorj NJ, Wirz OF, Röltgen K, Haraguchi E, Buzzanco AS III, Sibai M, et al.. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host & Microbe. 2021;29(12):1738–43.e4. doi: 10.1016/j.chom.2021.11.004 - DOI - PMC - PubMed
    1. Cunnington AJ, Riley EM. Suppression of vaccine responses by malaria: insignificant or overlooked? Expert Rev Vaccines. 2010;9(4):409–29. doi: 10.1586/erv.10.16 - DOI - PubMed

Publication types